Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 14Terminated 9Active not recruiting 8Recruiting 3Withdrawn 1Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Head & Neck 2Dermatologic 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 36Carcinoma, Non-Small-Cell Lung 17Small Cell Lung Carcinoma 16Neoplasms 14Lung Neoplasms 13Breast Neoplasms 8Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Recurrence 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Osteosarcoma 2Mesothelioma, Malignant 2Mesothelioma 2

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × atezolizumab × Clear all
NCT06161532 2026-06-05

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05581004 2026-05-11

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Recruiting
450 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06332755 2025-11-24

LB-LR1109

LG Chem

Phase 1 Recruiting
76 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡